PepTalk 2017
PepTalk 2017
Pipeline One Header

Cambridge Healthtech Institute’s Third Annual
Engineering Next-Generation Cancer Immunotherapies
New Science and Technologies for Protein Engineers and Discovery Scientists
to Support Development of Novel Immunotherapeutics and Treatment Combinations

January 9-10, 2017 | Hilton San Diego Bayfront | San Diego, CA

A succession of strong clinical successes by antibody therapeutics against the mainstream checkpoint targets has spawned a surge of interest from across the industry in advancing novel immunotherapeutics and agents that perform well in treatment combinations. Cambridge Healthtech Institute’s Third Annual Engineering Next-Generation Cancer Immunotherapies meeting offers important updates on scientific strategies and technologies that will be used by protein engineers and discovery scientists to support the development of the next wave of highly efficacious cancer immunotherapies.

Preliminary Agenda


KEYNOTE PRESENTATION: An NIH Perspective on Emerging Target Classes for Cancer Immunotherapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology National Cancer Institute, NIH

New Pathways For T-Cell Costimulation and Coinhibition

Xingxing Zang, M.Med., Ph.D., Miriam Mandel Faculty Scholar in Cancer Research Associate Professor, Microbiology & Immunology, Albert Einstein College of Medicine

Emerging Predictive Biomarkers for Cancer Immunotherapy

Sandip P. Patel, M.D., Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics, Thoracic Oncology, Moores Cancer Center, University of California, San Diego

APTIRTM Bispecifics, A Novel Platform for Development of Immuno-Oncology Therapeutics

Jane Gross, Ph.D., Vice President, Research and Development, Emergent Biosolutions

Hexavalent Single-Chain TNFSF-RBD-FC Fusion Proteins for Cancer Immunotherapy

Oliver Hill, Ph.D., ‪Vice President, Molecular Biology Apogenix GmbH‬, Germany


Mechanisms of Action for the Application of BiTE Antibodies in Immunotherapy Combinations

Tara Arvedson, Ph.D., Principal Scientist, Oncology Research, Amgen

Bispecific Antibodies for T Cell Redirection and Dual Checkpoint Blockade

John Desjarlais, Ph.D., CSO, Xencor

Design and Engineering for Polyclonal Antibodies

Birgit Schoeberl, Ph.D., ‪Senior Vice President, Discovery, Merrimack Pharmaceuticals

Chemically Programmed Bispecific Antibodies

Christoph Rader, Ph.D., Associate Professor, Cancer Biology and Molecular Therapeutics, The Scripps Research Institute

Combination Therapy of CAR T-Cells and Checkpoint Blockade

Prasad S. Adusumilli, M.D., FACS, Deputy Chief, Thoracic Service, Memorial Sloan Kettering Cancer Center


The 2.3 Angstrom Structure of Pembrolizumab, a Full-Length Anti-PD1 Therapeutic IgG4 Antibody

Giovanna Scapin, Ph.D., Senior Principal Scientist, Structural Biology, Merck

Affinity and Epitope Interplay in Antibody Efficacy

Dimiter S. Dimitrov, Ph.D., Senior Investigator, National Cancer Institute, NIH

Application of Structural Biology in Understanding the Mechanisms of Action in Cancer Immunotherapies

John Williams, Ph.D., Associate Professor, Molecular Medicine, Director, X-Ray Crystallography Core, Beckman Institute, City of Hope

Improving Immunotherapy with the HexaBody Platform

Paul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Genmab, Denmark

For questions about the meeting, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470